Idenix Pharma (IDIX) Posts Q2 Loss of $0.23, Wider than Views; Updates on Hepatitis C Virus Programs
Tweet Send to a Friend
Idenix Pharmaceuticals Inc. (Nasdaq: IDIX) reports Q2 loss of $0.23, versus the analyst estimate of ($0.15). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
